Engaging men through HIV self-testing with differentiated care to improve ART initiation and viral suppression among men in Malawi (ENGAGE): A study protocol for a randomized control trial.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
12
2022
accepted:
22
01
2023
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Men experience twice the mortality of women while on ART in sub-Saharan Africa (SSA) largely due to late HIV diagnosis and poor retention. Here we propose to conduct an individually randomized control trial (RCT) to investigate the impact of three-month home-based ART (hbART) on viral suppression among men who were not engaged in care. A programmatic, individually randomized non-blinded, non-inferiority-controlled trial design (ClinicalTrials.org NCT04858243). Through medical chart reviews we will identify "non-engaged" men living with HIV, ≥15years of age who are not currently engaged in ART care, including (1) men who have tested HIV-positive and have not initiated ART within 7 days; (2) men who have initiated ART but are at risk of immediate default; and (3) men who have defaulted from ART. With 1:1 computer block randomization to either hbART or facility-based ART (fbART) arms, we will recruit men from 10-15 high-burden health facilities in central and southern Malawi. The hbART intervention will consist of 3 home-visits in a 3-month period by a certified male study nurse ART provider. In the fbART arm, male participants will be offered counselling at male participant's home, or a nearby location that is preferred by participants, followed with an escort to the local health facility and facility navigation. The primary outcome is the proportion of men who are virally suppressed at 6-months after ART initiation. Assuming primary outcome achievement of 24.0% and 33.6% in the two arms, 350 men per arm will provide 80% power to detect the stated difference. Identifying effective ART strategies that are convenient and accessible for men in SSA is a priority in the HIV world. Men may not (re-)engage in facility-based care due to a myriad of barriers. Two previous trials investigated the impact of hbART on viral suppression in the general population whereas this trial focuses on men. Additionally, this trial involves a longer duration of hbART i.e., three months compared to two weeks allowing men more time to overcome the initial psychological denial of taking ART.
Sections du résumé
BACKGROUND
Men experience twice the mortality of women while on ART in sub-Saharan Africa (SSA) largely due to late HIV diagnosis and poor retention. Here we propose to conduct an individually randomized control trial (RCT) to investigate the impact of three-month home-based ART (hbART) on viral suppression among men who were not engaged in care.
METHODS AND DESIGN
A programmatic, individually randomized non-blinded, non-inferiority-controlled trial design (ClinicalTrials.org NCT04858243). Through medical chart reviews we will identify "non-engaged" men living with HIV, ≥15years of age who are not currently engaged in ART care, including (1) men who have tested HIV-positive and have not initiated ART within 7 days; (2) men who have initiated ART but are at risk of immediate default; and (3) men who have defaulted from ART. With 1:1 computer block randomization to either hbART or facility-based ART (fbART) arms, we will recruit men from 10-15 high-burden health facilities in central and southern Malawi. The hbART intervention will consist of 3 home-visits in a 3-month period by a certified male study nurse ART provider. In the fbART arm, male participants will be offered counselling at male participant's home, or a nearby location that is preferred by participants, followed with an escort to the local health facility and facility navigation. The primary outcome is the proportion of men who are virally suppressed at 6-months after ART initiation. Assuming primary outcome achievement of 24.0% and 33.6% in the two arms, 350 men per arm will provide 80% power to detect the stated difference.
DISCUSSION
Identifying effective ART strategies that are convenient and accessible for men in SSA is a priority in the HIV world. Men may not (re-)engage in facility-based care due to a myriad of barriers. Two previous trials investigated the impact of hbART on viral suppression in the general population whereas this trial focuses on men. Additionally, this trial involves a longer duration of hbART i.e., three months compared to two weeks allowing men more time to overcome the initial psychological denial of taking ART.
Identifiants
pubmed: 36827327
doi: 10.1371/journal.pone.0281472
pii: PONE-D-22-29436
pmc: PMC9956026
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT04858243']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0281472Subventions
Organisme : FIC NIH HHS
ID : K01 TW011484
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH122308
Pays : United States
Informations de copyright
Copyright: © 2023 Choko et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Lancet Glob Health. 2020 Oct;8(10):e1305-e1315
pubmed: 32971053
PLoS Med. 2021 Oct 21;18(10):e1003839
pubmed: 34673765
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):375-385
pubmed: 30570525
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
BMC Public Health. 2021 Jan 6;21(1):60
pubmed: 33407298
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
PLoS One. 2017 May 24;12(5):e0177168
pubmed: 28542309
PLoS Med. 2012 Feb;9(2):e1001167
pubmed: 22346735
PLoS Med. 2019 Jan 2;16(1):e1002719
pubmed: 30601823
Lancet. 2019 Jun 22;393(10190):2535-2549
pubmed: 31155270
J Int AIDS Soc. 2009 Sep 29;12:22
pubmed: 19788755
Lancet. 2021 Jun 5;397(10290):2130-2132
pubmed: 34087108
Bull World Health Organ. 2021 Sep 01;99(9):618-626
pubmed: 34475599
Trop Med Int Health. 2015 Dec;20(12):1634-5
pubmed: 26325025
Trials. 2017 Jul 24;18(1):349
pubmed: 28738857
PLoS Med. 2015 Apr 07;12(4):e1001811
pubmed: 25849433
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
AIDS Behav. 2018 Feb;22(2):497-512
pubmed: 28155039
AIDS. 2011 Jun 1;25(9):1189-97
pubmed: 21505309
AIDS Behav. 2018 Aug;22(8):2468-2479
pubmed: 29777420
Lancet. 2009 Dec 19;374(9707):2080-2089
pubmed: 19939445
AIDS Care. 2010 Dec;22(12):1562-8
pubmed: 20582753
PLoS Med. 2019 Oct 29;16(10):e1002959
pubmed: 31661487
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
PLoS One. 2018 Jan 26;13(1):e0188488
pubmed: 29373574
Trials. 2019 Dec 30;20(1):798
pubmed: 31888701
JAMA. 2014 Jul 23-30;312(4):372-9
pubmed: 25038356
AIDS Educ Prev. 2013 Feb;25(1):14-24
pubmed: 23387948
PLoS One. 2021 Mar 10;16(3):e0247483
pubmed: 33690691
AIDS. 2013 Jan 28;27(3):417-25
pubmed: 22948271
J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):71-6
pubmed: 17031319
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
Lancet HIV. 2019 Mar;6(3):e191-e200
pubmed: 30777726
J Int AIDS Soc. 2016 Nov 08;19(1):21106
pubmed: 27834182
BMC Public Health. 2010 Dec 17;10:769
pubmed: 21167040